LeMaitre Vascular, Inc. $LMAT Shares Sold by JPMorgan Chase & Co.

JPMorgan Chase & Co. reduced its position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 18.6% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 121,988 shares of the medical instruments supplier’s stock after selling 27,800 shares during the period. JPMorgan Chase & Co. owned approximately 0.54% of LeMaitre Vascular worth $10,675,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the business. Parkside Financial Bank & Trust boosted its position in shares of LeMaitre Vascular by 1,913.3% during the 2nd quarter. Parkside Financial Bank & Trust now owns 302 shares of the medical instruments supplier’s stock valued at $25,000 after purchasing an additional 287 shares in the last quarter. Cornerstone Planning Group LLC boosted its holdings in LeMaitre Vascular by 534.0% during the third quarter. Cornerstone Planning Group LLC now owns 336 shares of the medical instruments supplier’s stock worth $30,000 after buying an additional 283 shares in the last quarter. First Horizon Corp acquired a new position in LeMaitre Vascular in the third quarter worth approximately $39,000. Geneos Wealth Management Inc. increased its holdings in shares of LeMaitre Vascular by 250.3% in the first quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock valued at $47,000 after buying an additional 398 shares in the last quarter. Finally, EverSource Wealth Advisors LLC bought a new position in shares of LeMaitre Vascular in the second quarter valued at $47,000. 84.64% of the stock is currently owned by institutional investors.

LeMaitre Vascular Stock Down 0.2%

Shares of LeMaitre Vascular stock opened at $106.15 on Friday. LeMaitre Vascular, Inc. has a 1 year low of $71.42 and a 1 year high of $115.33. The company has a market cap of $2.42 billion, a P/E ratio of 42.29, a P/E/G ratio of 3.06 and a beta of 0.66. The company has a current ratio of 12.89, a quick ratio of 10.95 and a debt-to-equity ratio of 0.43. The stock has a 50-day moving average price of $88.82 and a 200 day moving average price of $88.73.

LeMaitre Vascular (NASDAQ:LMAT) last issued its earnings results on Wednesday, February 25th. The medical instruments supplier reported $0.68 earnings per share for the quarter, beating analysts’ consensus estimates of $0.67 by $0.01. The company had revenue of $64.45 million for the quarter, compared to the consensus estimate of $62.98 million. LeMaitre Vascular had a return on equity of 14.72% and a net margin of 23.13%.The firm’s quarterly revenue was up 15.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.49 EPS. LeMaitre Vascular has set its FY 2026 guidance at 2.810-3.010 EPS and its Q1 2026 guidance at 0.640-0.690 EPS. As a group, analysts expect that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 26th. Shareholders of record on Thursday, March 12th will be paid a dividend of $0.25 per share. This is an increase from LeMaitre Vascular’s previous quarterly dividend of $0.20. The ex-dividend date of this dividend is Thursday, March 12th. This represents a $1.00 dividend on an annualized basis and a dividend yield of 0.9%. LeMaitre Vascular’s dividend payout ratio (DPR) is 31.87%.

Wall Street Analysts Forecast Growth

LMAT has been the subject of several research reports. Wall Street Zen raised LeMaitre Vascular from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. Wells Fargo & Company increased their price target on LeMaitre Vascular from $87.00 to $94.00 and gave the company an “equal weight” rating in a research report on Thursday, February 26th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $95.00 price objective on shares of LeMaitre Vascular in a research note on Monday, November 10th. Weiss Ratings cut shares of LeMaitre Vascular from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, February 24th. Finally, Barrington Research boosted their price target on shares of LeMaitre Vascular from $95.00 to $105.00 and gave the company an “outperform” rating in a report on Thursday, February 26th. Three analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $105.80.

Insider Activity

In other news, insider Trent G. Kamke sold 1,044 shares of the company’s stock in a transaction on Friday, February 27th. The shares were sold at an average price of $110.29, for a total value of $115,142.76. Following the transaction, the insider directly owned 6,677 shares of the company’s stock, valued at approximately $736,406.33. This represents a 13.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director David B. Roberts sold 8,464 shares of the business’s stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $106.80, for a total value of $903,955.20. Following the completion of the transaction, the director owned 17,979 shares in the company, valued at $1,920,157.20. This trade represents a 32.01% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 215,438 shares of company stock worth $23,062,911 in the last ninety days. Corporate insiders own 9.50% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.